Membranoproliferative Glomerulonephritis Workshop

描述(由申请人提供)： 关于膜增生性肾炎II型(MPGN2)的第一次国际会议将于2004年8月14日在马萨诸塞州的波士顿举行。这次会议的目标是确定和确定与MPGN2相关的研究问题和问题，以促进对这种疾病的科学兴趣，并鼓励研究，从而开发出预防疾病进展和疾病复发的治疗方法。为实现这一目标，确立了以下目标： 1)汇聚在补体介导性疾病方面有专长的基础科学家、在肾小球疾病方面有专长的肾病病理学家，以及在肾小球肾炎方面有专长的临床肾病学家； 2)重点研究MPGN2的致病机制； 3)确定应开展的科学研究领域，以便开发预防MPGN2进展和复发的治疗方法； 上午的会议将包括关于MPGN2的临床方面的讲座，描述其呈现和自然历史，关于MPGN2的病理分类的讲座，讨论可能的疾病异质性，以及关于MPGN2的知识现状的讲座，因为MPGN2是从缺乏补体成分的小鼠突变中获得的。会议将继续根据介绍性讲座提出的问题、与会者在会议前向国际和平倡议会议提出的问题以及会议期间出现的相关议题进行重点圆桌讨论。圆桌讨论将由非政府组织会议主持，以确保实现会议目标。在圆桌讨论之后，一位临床科学家将发表总结，概述提出的工作和为开发治疗MPGN2的疗法而应开展的建议研究路线。

DESCRIPTION (provided by applicant): The first international conference on Membranoproliferative Glomerulonephritis Type II (MPGN2) will be held on August 14, 2004, in Boston, Massachusetts. The goal of this conference is to identify and define the research problems and issues associated with MPGN2 in order to promote scientific interest in this disease and stimulate research leading to the development of therapies to prevent disease progression and disease recurrence. To achieve this goal, the following objectives have been established: 1) To bring together basic scientists with expertise in complement-mediated diseases, nephropathologists with expertise in glomerulopathies, and clinical nephrologists with expertise in glomerulonephritis; 2) To focus on the pathogenic mechanisms that lead to MPGN2; 3) To define areas of scientific investigation that should be pursued in order lead to the development of therapies to prevent progression and recurrence of MPGN2; Morning sessions will include a lecture on the clinical aspects of MPGN2 describing its presentation and natural history, a lecture on the pathological classification of MPGN2 discussing possible disease heterogeneity, and a lecture on the current state of-knowledge of MPGN2 as gleaned from mouse mutants deficient in components of complement. The conference will continue with a focused round-table discussion based on questions raised by the introductory lectures, questions submitted to the conference PI by the participants prior to the meeting, and relevant topics that arise during the course of the conference. The round-table discussion will be chaired by the conference PI to ensure that conference objectives are met. Following the round-table discussion, a clinical-scientist will deliver a summary outlining the work presented and the recommended lines of investigation that should be pursued in order to develop therapies to treat MPGN2.